Some human cells possess a poorly defined antiviral activity, the existence of which is indicated by studies of the HIV-1 accessory protein, Vpu, that inhibits the release of certain enveloped virus particles. Specifically, Vpu is required for efficient HIV-1 particle release in certain human cells [1] [2] [3] , and HeLa cells are a prototypic example of cells that exhibit this requirement 4 . However, Vpu is completely dispensable for efficient HIV-1 particle release in some other human cells and in the African green monkey cell line COS-7 5, 6 . Notably, fusion of HeLa cells with COS-7 cells results in heterokaryons that exhibit the properties of HeLa cells 7 , suggesting the existence of an inhibitor of virion release that is expressed in HeLa cells, but not in COS cells, and is antagonized by Vpu. Moreover, Vpu stimulates the release of retrovirus particles as diverse as HIV-1 and murine leukaemia virus (MLV) from HeLa cells 4 , as well as virus-like particles based on the structural protein of Ebola virus 8 , further suggesting that the inhibitor works in a nonspecific way to block envelope virus particle release.
Early analyses of cells infected with Vpu-deleted HIV-1 strains revealed that virions accumulate within intracellular vacuoles and at the cell surface, at the expense of particle release 3, 4 . Recent work has shown that the intracellular virions are primarily localized in CD63 1 endosomes 6, 8 , and that they accumulate at this location as a result of their internalization from the cell surface 6, [8] [9] [10] . Moreover, HIV-1 particles that are retained by cells owing to the absence of Vpu are fully formed and mature, and can be released from cell surfaces by protease, particularly when their endocytosis is blocked 6, 8 . Thus, the inhibitor that is counteracted by Vpu seems to induce adherence of nascent virions to the surface of cells, after completion of their assembly, and from where they may be internalized. We recently found that a requirement for Vpu during HIV-1 virion and Ebolavirus-like particle release can be induced or enhanced in fibroblasts or T cells by treatment with interferon-a (IFN-a) 8 . Notably, the nature of the HIV-1 release defect that accompanies Vpu deletion in these IFN-a-treated cells precisely recapitulates that observed constitutively in HeLa cells 6, 8 . Thus, these data suggest that the inhibitor that is antagonized by Vpu is an IFN-a-induced, cell-surfaceprotein-based tether, that we term 'tetherin'. However, although evidence for the existence of tetherin is quite considerable, it is indirect, and the identity of tetherin is unknown.
Identification of tetherin candidates
To identify tetherin candidates we applied several constraints based on the aforementioned studies that predicted its distribution and nature. First, tetherin should be constitutively expressed in a cell line (HeLa) where HIV-1 Vpu is constitutively required for efficient retrovirus particle release 4 , but not in cells where Vpu is dispensable (for example, HOS, 293T or HT1080 cells 6, 8 ; Supplementary Table 1) . Second, because a requirement for Vpu during HIV-1 release becomes evident after IFN-a treatment in 293T and HT1080 8 cells (Supplementary Table 1 ) and is enhanced by IFN-a treatment in Jurkat cells and primary lymphocytes 8 , then tetherin expression should reflect this property. Moreover, because Vpu-defective HIV-1 release seems to be blocked after the fission of cell and virion membranes 3, 4, 6 , tetherin should be a secreted or membrane-associated protein. Although none of the aforementioned criteria alone would provide sufficient discriminatory power to identify tetherin, we reasoned that their simultaneous application might reduce candidates to a reasonable number to be tested individually.
Microarray analyses of messenger RNAs expressed in the aforementioned untreated and IFN-a-treated cell lines revealed few (,10) candidates that conformed to the above criteria. Among these was CD317, a membrane protein of unknown function 11 , as well as three 'interferon-induced transmembrane proteins', IFITM1, IFITM2 and IFITM3 (Fig. 1a and Supplementary Table 2 ). On the basis of their expression levels in the various cell lines, CD317 appeared to be the most compelling of these candidates (Fig. 1a and Supplementary Table 2 ). Indeed, its expression, as measured by microarray or quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis, was .20-fold higher in HeLa than in HOS cells, was induced .20-fold by IFN-a in 293T and HT1080 cells, and was induced two-to fivefold in Jurkat cells (Fig. 1b, c) . Moreover, IFN-a treatment accentuates the requirement for Vpu in HIV-1 replication in primary lymphocytes 8 and, concordantly, CD317 mRNA was induced by IFN-a in CD4 1 enriched lymphocytes from two donors (Fig. 1d) .
Transfection of 293T cells with wild-type (HIV-1(WT)) and Vpudeleted (HIV-1(delVpu)) proviral plasmids generated, as expected, equivalent yields of HIV-1 particles, determined using western blot or infectious virion measurements (Fig. 1e, f) . However, HIV-1 (delVpu), but not HIV-1(WT), virion production was strongly inhibited by co-expressed CD317. Notably, Gag protein expression or processing was not affected by CD317 (Fig. 1e) , suggesting that the candidate tetherin indeed inhibited particle release. Conversely, similar transient transfection assays revealed that overexpression of IFITM1, IFITM2 or IFITM3 did not affect HIV-1(delVpu) release (data not shown).
Inhibition of retrovirus release by tetherin
Because Vpu affects CD4 expression as well as virion release 12 and because CD4 can interfere with virus release and infectivity 13, 14 , the effect of the candidate tetherin on HIV-1(WT) and HIV-1(delVpu) replication was analysed using single-cycle HIV-1 replication assays in CD4 2 cells. These assays were done in cells that do (HeLa) or do not (293T, HT1080) constitutively express CD317. Furthermore, derivatives of 293T and HT1080 cells that stably expressed CD317 were established via retroviral vector transduction, and qRT-PCR analyses revealed that CD317 mRNA was only moderately overexpressed (,2-6-fold more abundant than in HeLa cells) in these cell lines. Crucially, stable CD317 expression reduced Vpu-defective HIV-1 virion yield by .100-fold (293T cells) and ,80-fold (HT1080 cells) over a single replication cycle ( Fig. 2a-d ). Conversely, CD317 had only marginal effects (,2-fold) on HIV-1(WT) yield. Viral Gag protein expression in HIV-1(WT)-or HIV-1(delVpu)-infected 293T or HT1080 cells was equal in the presence or absence of CD317 (Fig. 2c, d ), indicating that all preceding steps in HIV-1 replication were unaffected and that CD317 specifically inhibited HIV-1 virion release. In addition, transfection of 293T cells with vectors expressing MLV GagPol revealed that stable expression of CD317 markedly reduced the yield of MLV particles, without affecting MLV Gag expression (Fig. 2e) . Moreover, inhibition of MLV particle release by CD317 was almost completely abolished when Vpu was coexpressed with MLV GagPol. (Fig. 2e) .
In single-cycle HIV-1 replication assays, conducted in HeLa cells that constitutively express CD317, HIV-1(delVpu) virions were released approximately 20-fold less efficiently than HIV-1(WT) counterparts (Fig. 2f, g ). To determine whether CD317 was required for this phenotype, the same assay was done using HeLa cells transfected with a CD317-targeted short interfering RNA (siRNA) pool that effectively knocked down expression of the corresponding haemagglutinin (HA)-tagged protein ( Supplementary Fig. 1 ), or a control siRNA pool. CD317-targeted siRNAs, but not control siRNAs, enhanced the yield of HIV-1(delVpu) from HeLa cells by ,13-fold, but had negligible effects on HIV-1(WT) yield (Fig. 2g) . Notably, CD317 knockdown had no effect on Gag expression and processing (Fig. 2f) ; rather it relieved a requirement for Vpu during particle release.
CD317 (referred to hereafter as tetherin) has an unusual topology, in that it harbours an amino-terminal cytoplasmic tail, a singlemembrane-spanning sequence, a predicted extracellular coiled-coil domain and a putative carboxy-terminal glycosyl phosphatidylinositol (GPI) membrane anchor 15, 16 (Fig. 3a) . All of the aforementioned assays were done using an authentic, untagged version of tetherin.
However, to facilitate more detailed analyses, an N-terminally HAepitope-tagged tetherin derivative was generated, and this protein accurately recapitulated the antiviral properties of the untagged molecule (Fig. 3b, c) . HA-tetherin exhibited a complex pattern of distribution in cells, suggesting that it localized to multiple membranous compartments, including the plasma membrane (Supplementary Fig. 2) . Moreover, tetherin migrated as several species in SDS-PAGE analyses, presumably as a result of heterogeneous glycosylation 11 ( Fig. 3b) . A tetherin variant with a truncated N-terminal cytoplasmic tail (delCT) migrated as a single species in SDS-PAGE analyses, and its subcellular distribution was aberrant, suggesting that it remained non-glycosylated or uniformly glycosylated, and failed to complete proper transport through the secretory pathway ( Fig. 3b and Supplementary Fig. 2) . Notably, tetherin(delCT) did not affect HIV-1(delVpu) particle release (Fig. 3b, c) . Removal of the putative GPI modification signal in tetherin, (delGPI), increased tetherin protein levels but did not overtly alter glycosylation or subcellular distribution ( Fig. 3b and Supplementary Fig. 2 ). However, removal of the putative GPI anchor completely abolished tetherin's ability to inhibit HIV-1(delVpu) release (Fig. 3b, c) .
Effects of tetherin on nascent HIV-1 particles
In circumstances where HIV-1 release requires Vpu expression, Vpudefective HIV-1 virions assemble and mature, but remain tethered to the surface of cells 3, 4, 6 . Thereafter, a proportion of virions are internalized and accumulate in endosomes 6, 9, 10 . To determine whether tetherin induced this phenotype, 293T cells were transiently co-transfected with plasmids expressing HIV-1 Gag-GFP, tetherin and/or Vpu. Tetherin markedly increased the proportion of cells that contained prominent intracellular accumulations of Gag-GFP puncta, which were often associated with CD63
1 endosomes (Fig.  4a, b and Supplementary Fig. 3a) . Conversely, a mutant tetherin (delGPI) that did not inhibit HIV-1(delVpu) release did not affect the distribution of Gag-GFP (Supplementary Fig. 3a) . Importantly, tetherin did not induce intracellular accumulation of Gag-GFP when Vpu was co-expressed ( Fig. 4a and Supplementary Fig. 3a) . Moreover, accumulation of Gag-GFP puncta in the endosomes of 293T cells stably expressing tetherin was blocked by a dominant-negative 
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Rab5a mutant (S34N) as well as by Vpu (Fig. 4c and Supplementary  Fig. 3b, c) , suggesting that tetherin-induced association of Gag-GFP with CD63
1 compartments occurred via endocytic uptake of nascent particles from the plasma membrane. Consistent with this notion, when swollen endosomes were induced by expression of a dominantactive Rab5a mutant (Q79L), tetherin induced the appearance of Gag-GFP puncta within the swollen endosomal lumen (Fig. 4c) . Similar experiments, done in HT1080 cells stably expressing tetherin and infected with an HIV-1 strain carrying YFP inserted into the stalk region of the Gag matrix domain (HIV/MA-YFP) 17, 18 , showed that YFP-positive puncta accumulated in intracellular compartments of tetherin-expressing cells, specifically when a Vpu-deleted HIV/MA-YFP virus was used (Supplementary Fig. 3d) .
Electron microscopic analysis of unmodified HT1080 cells, infected with HIV-1(WT) or HIV-1(delVpu), revealed occasional budding structures and mature virions associated with the plasma membrane (Fig. 4d, e) . In HT1080 cells stably expressing tetherin and infected with HIV-1(WT), virions were found associated with the plasma membrane at marginally greater frequency (Fig. 4f) . In stark contrast, HIV-1(delVpu) infection of tetherin-expressing cells often resulted in massive accumulations of mature virion particles on cell surfaces ( Fig. 4g and Supplementary Fig. 4 ). Mature HIV-1(delVpu) virions were also frequently observed in intracellular compartments in tetherin-expressing HT1080 cells ( Supplementary Fig. 4) , consistent with the notion that the particles retained by tetherin can be endocytosed (Fig. 4b, c) .
To determine whether tetherin caused protein-mediated tethering of HIV-1 to cell surfaces, we used an assay in which tethered virions are recovered from cell surfaces by protease 'stripping' 6, 8 . In HIV-1-transfected or -infected 293T cell cultures, the majority of virions that can be recovered are constitutively released into the extracellular medium, irrespective of Vpu expression, and only a minor fraction of the total virion output is recovered by protease stripping of cell surfaces 8 . Similarly, In 293T cells stably expressing tetherin, HIV-1 (WT) virions were also predominantly constitutively released and only a minor fraction were recovered by protease stripping (Fig. 4h) . Conversely, recovery of the majority of HIV-1(delVpu) virions required protease stripping from the surface of tetherinexpressing 293T cells. In similar experiments, co-expression of Rab5a(S34N) slightly reduced the overall production of HIV-1 (WT) and HIV-1(delVpu). However, presumably because virion endocytosis was blocked (Fig. 4c) , the recovery of HIV-1(delVpu) by protease stripping of the tetherin-expressing cells' surface was enhanced and, in fact, equalled the yield of constitutively released HIV-1(WT) virions (Fig. 4h) .
Localization of HIV-1 Gag, Vpu and tetherin
Notably, the intracellular compartments in which Gag-GFP or HIV/ MA-YFP puncta accumulated in transfection or infection assays were often HA-tetherin-positive ( Fig. 5a and Supplementary Fig.  5 ). Moreover, YFP puncta that were localized at the surface of HIV/MA-YFP(delVpu)-infected cells were also often positive for HA-tetherin ( Supplementary Fig. 5 ). It is possible, therefore, that tetherin is directly responsible for the retention of nascent virions on cell surfaces and their movement into intracellular compartments. Notably, association of Gag-GFP or HIV/MA-YFP puncta with HAtetherin was prevented by co-expression of Vpu (Fig. 5a and Supplementary Fig. 5 ), and Vpu itself co-localized almost perfectly with HA-tetherin (Fig. 5b) . Although Vpu did not have overt effects on tetherin levels or subcellular distribution (Fig. 3b, Fig. 5b and data not shown), only a minor fraction of HA-tetherin was associated with the plasma membrane, thus its potential removal from that site was difficult to evaluate. Notably, an inactive Vpu mutant in which the transmembrane domain was replaced with that of CD8 (Vpu(CD8TM)) 6 did not co-localize extensively with HA-tetherin (Fig. 5b) . Conversely, a Vpu mutant whose activity was partly impaired by truncation of its cytoplasmic tail at residue 50 (Vpu(1-50), Supplementary Fig. 6 ) co-localized extensively, albeit incompletely, with HA-tetherin, and caused the distribution of tetherin to be more diffuse and plasma-membrane associated (Fig. 5b) . Thus, these results suggest a direct or indirect association between tetherin and Vpu, perhaps involving the Vpu transmembrane domain.
Discussion
Overall, tetherin specifically inhibited retrovirus particle release in the absence of Vpu and its expression precisely recapitulated the characteristic HIV-1 particle release defects that have previously been associated with loss of Vpu function [2] [3] [4] 6, 8, 9 . Moreover, tetherin co-localized with Vpu and, when Vpu was absent, virions were associated with tetherin at the cell surface and in intracellular compartments. These findings strongly suggest that a major function of the HIV-1 Vpu protein is to facilitate virus spread by antagonizing tetherin-induced particle retention. Notably, previous work has shown that Vpu can enhance the release of a wide range of retroviruses, as well as Ebola virus, in HeLa cells or other cells treated with IFN-a 4, 8 , suggesting that tetherin acts in a rather nonspecific way to inhibit enveloped virion release. This prediction is borne out by our findings that tetherin can indeed inhibit the release of MLV as well as HIV-1. At present, it is unclear whether only the human form of tetherin has this antiviral function. Orthologues are present in other mammals, but Vpu is not required for efficient HIV-1 particle release from untreated African green monkey COS cells 5 , and fails to stimulate particle release that has been is inhibited by IFN-a treatment 8 . It will be interesting to determine whether these apparently hostspecies-specific differences in Vpu activity reflect divergence in tetherin sequence and function.
Tetherin is known to be expressed on terminally differentiated B cells 19 , bone marrow stromal cells (hence the name BST2) 11 and plasmacytoid dendritic cells 20 . Tetherin has also previously been shown to be broadly expressed on IFN-a induction 19, 20 . Because tetherin is GPI-modified, it may partition into cholesterol-rich domains on the plasma membrane 15 . Potentially, this property could drive or facilitate encounters with assembling HIV-1 (or other enveloped virus) particles, which have a similar lipid composition 21 . Although we have not yet determined whether tetherin is actually incorporated into virion particles, the fact that electron microscopic analysis shows that, in the absence of Vpu, HIV-1 particles appeared to be tethered to each other as well as to cells suggests that this may be the case. Moreover, given tetherin's unusual topology, as well as its propensity to dimerize 19 , several possible configurations could be imagined in which tetherin might nonspecifically tether virions to cell membranes, and to each other ( Supplementary Fig. 7) .
Interestingly, tetherin protein levels are decreased by expression of the Kaposi's sarcoma herpesvirus K5 protein 22 . This fact, and the observations that tetherin inhibits divergent retroviruses and is widely expressed in the presence of IFN-a 20 , raises the possibility that tetherin might be an important component of the broad innate IFNa-induced antiviral defence against enveloped viruses. Future work will determine the spectrum of viruses against which tetherin is active, precisely how tetherin induces virion retention, and how its action is counteracted by the HIV-1 Vpu protein.
METHODS SUMMARY
Microarray analyses. Total RNA from the various cell lines that were either untreated or treated with IFN-a was used to interrogate microarrays (Illumina). qRT-PCR. Total RNA from untreated or IFN-a-treated cells was used to generate cDNA which was analysed using primer pairs for CD317 and GAPDH (Superarray Bioscience Corporation). Tetherin expression constructs. Tetherin was transiently expressed using pCR3.1/HA-based plasmids or stably expressed using LHCX-based retroviral vectors. The delCT and delGPI variants of tetherin lacked the N-terminal 20 amino acids and C-terminal 19 amino acids, respectively. Single-cycle HIV-1 replication and transfection-based virion release assays. 293T cells were transfected with wild-type (HIV-1(WT)) or Vpu-deleted (HIV-1 (delVpu)) proviral plasmids, along with tetherin expression plasmids. Alternatively, HeLa cells (that were either untransfected or transfected with siRNAs), 293T cells, or HT1080 cells were infected with VSV-G-pseudotyped HIV-1(WT) or HIV-1(delVpu). Thereafter, culture supernatants and infected cells were collected. Virus particle pellets collected from culture supernatants and corresponding cell lysates were analysed by western blot assays using anti-p24 monoclonal antibodies. Infectious virus yields were determined using HeLaTZMbl indicator cells. Protease stripping assays. 293T cells stably expressing tetherin were transfected with proviral plasmids. Constitutively released particles or particles that were ARTICLES released after buffer wash or subtilisin stripping, as well as corresponding cell lysates, were analysed by western blotting. Microscopy. Cells, plated on coverslips, were transfected with combinations of plasmids expressing HIV-1 Gag-GFP, tetherin, Vpu, and/or Rab5a mutants. Alternatively, cells were infected with VSV-G-pseudotyped HIV-1/MA-YFP. Anti-HA or anti-CD63 antibodies were used for staining. Microscopy was done using a Deltavision suite. For electron microscopy, HT1080 cells were infected with VSV-G-pseudotyped HIV-1(WT) or HIV-1(delVpu). Sections were stained with uranyl acetate and lead citrate and observed with a FEI G2 Tecnai TEM.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
